Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2006

View Archived Issues

Kadian effective in treating non-malignant pain

Statins, NSAIDs and calcium channel blockers linked to reduced melanoma risk

CycloSal nucleotides may optimize anti-HIV therapy

Elan offers development updates

BioMarin highlights positive quarter

NPY5 receptor antagonist effective in rodent obesity models

Dextromethorphan/quinidine improves pseudobulbar affect in multiple sclerosis

HCV peptide vaccine safe and active in randomized study

AC-100 increases osteogenic activity of BMP2

Edotecarin enhances in vivo antitumor activity of other treatments

TorreyPines Therapeutics' tezampanel completes phase I trials for acute migraine

AstraZeneca strengthens biological therapeutics divisions by making bid on CAT

Axonyx completes phase I clinical trial with Posiphen

Jurnista completes European mutual recognition procedure

EntreMed evaluates Panzem NCD in phase II clinical trial for carcinoid cancer

Nereus Pharmaceuticals' anticancer proteasome inhibitor enters clinical trials

BioAlliance Pharma begins pivotal phase III trial of Loramyc for treatment for OPC

Oxigene's Combretastatin A4P granted orphan drug designation for ovarian cancer

Pixantrone combination regimen shown effective in relapsed indolent NHL

New agents for treating thrombosis and related disorders reported in recent patents

Recent patents disclose novel treatment strategies for cardiovascular disorders

Favorable phase II results with CVac in ovarian cancer reported

Recent Pfizer and Scynexis patents report novel therapeutics for HCV infection

FDA meeting guides accelerated clinical development of PI-88

Recruitment completed for pivotal phase III alitretinoin trial for severe chronic hand dermatitis

Basilea's ceftobiprole enters phase III trial for community-acquired pneumonia

FDA approves Cesamet for cancer chemotherapy-associated nausea and vomiting

Exelon recommended by FDA Advisory Committee for additional indication

Hsp90 inhibitor shows activity in a murine model of choroidal neovascularization

Prodrugs of vidarabine demonstrate activity against vaccinia virus infections

Protein-based therapy for junctional epidermolysis bullosa shows efficacy in preclinical studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...